Amoxicillin and Clavulanate Potassium for Oral Suspension USP — Class II drug recall D-0151-2026
Ongoing recall by Teva Pharmaceuticals USA, Inc, reported 2025-11-12, distributed in CA, MS, OH. Subpotent drug; Clavulanate Potassium component
| Recall number | D-0151-2026 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Ongoing |
| Voluntary or mandated | Voluntary |
| Recalling firm | Teva Pharmaceuticals USA, Inc, Parsippany, NJ, United States |
| Recall initiated | 2025-10-13 |
| Classified | 2025-11-03 |
| Reported by FDA | 2025-11-12 |
| Distributed | CA, MS, OH |
| Quantity | 4,680 cartons |
| Reason classes | potency |
| Lot numbers | 100062316 |
| Expiration dates | 2026-01 |
Product
Amoxicillin and Clavulanate Potassium for Oral Suspension USP, 200 mg/28.5 mg per 5mL, 100 mL (when reconstituted), Rx only, manufactured in Canada by: Teva Canada Limited, Toronto, Canada M1B 2K9; Manufactured For: Teva Pharmaceuticals USA, Inc., Parsippany, NJ 07054 NDC 0093-2277-7.
Reason for recall
Subpotent drug; Clavulanate Potassium component
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0151-2026. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.